Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

July 20, 2006

Primary Completion Date

May 31, 2015

Study Completion Date

November 15, 2022

Conditions
Hodgkin's Lymphoma
Interventions
DRUG

Adriamycin®

Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.

DRUG

Vinblastine

Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.

DRUG

Nitrogen Mustard

Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.

DRUG

Cyclophosphamide

May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.

DRUG

Vincristine

Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.

DRUG

Bleomycin

Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.

DRUG

Etoposide

Given IV on Days 1 and 2 of weeks 1-10.

DRUG

Prednisone

Given PO every other day of weeks 1-12.

BIOLOGICAL

G-CSF

Given subcutaneously days 3-13, 16-26, 29-39, 42-52, 55-65, and 68-78 (as clinically indicated).

PROCEDURE

Radiotherapy

Participants receive radiotherapy after completion of 12 weeks of Stanford V chemotherapy.

Trial Locations (6)

38105

St. Jude Children's Research Hospital, Memphis

92123

Rady Children's Hospital San Diego, San Diego

94304

Stanford University Medical Center, Palo Alto

04102-3175

Maine Children's Medical Center, Portland

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER

NCT00352027 - Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter